- Home
- FCAP vs ACET Comparison
FCAP vs ACET Comparison
Compare FCAP & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCAP
- ACET
- Stock Information
- Founded
- FCAP 1891
- ACET 1947
- Country
- FCAP United States
- ACET United States
- Employees
- FCAP N/A
- ACET N/A
- Industry
- FCAP Savings Institutions
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- FCAP Finance
- ACET Health Care
- Exchange
- FCAP Nasdaq
- ACET Nasdaq
- Market Cap
- FCAP 125.9M
- ACET 111.9M
- IPO Year
- FCAP 1999
- ACET N/A
- Fundamental
- Price
- FCAP $44.01
- ACET $0.64
- Analyst Decision
- FCAP
- ACET Buy
- Analyst Count
- FCAP 0
- ACET 4
- Target Price
- FCAP N/A
- ACET $8.50
- AVG Volume (30 Days)
- FCAP 3.6K
- ACET 2.2M
- Earning Date
- FCAP 10-24-2025
- ACET 11-05-2025
- Dividend Yield
- FCAP 2.80%
- ACET N/A
- EPS Growth
- FCAP 25.19
- ACET N/A
- EPS
- FCAP 4.41
- ACET N/A
- Revenue
- FCAP $47,323,000.00
- ACET N/A
- Revenue This Year
- FCAP N/A
- ACET N/A
- Revenue Next Year
- FCAP N/A
- ACET N/A
- P/E Ratio
- FCAP $10.07
- ACET N/A
- Revenue Growth
- FCAP 15.22
- ACET N/A
- 52 Week Low
- FCAP $28.50
- ACET $0.45
- 52 Week High
- FCAP $53.85
- ACET $1.40
- Technical
- Relative Strength Index (RSI)
- FCAP 57.27
- ACET 31.44
- Support Level
- FCAP $42.71
- ACET $0.66
- Resistance Level
- FCAP $44.00
- ACET $0.71
- Average True Range (ATR)
- FCAP 0.80
- ACET 0.07
- MACD
- FCAP 0.20
- ACET -0.03
- Stochastic Oscillator
- FCAP 100.00
- ACET 7.83
About FCAP First Capital Inc.
First Capital Inc is the financial holding company of First Harrison Bank. Through its subsidiary, it operates as a federally-chartered savings bank that provides banking services to individuals and business customers across locations in America. The bank offers various loans which include residential loans, construction loans, commercial real estate loans and commercial business loans. It also provides consumer loans such as home equity and second mortgage loans, and automobile and truck loans.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.